Centessa Q3 net loss $53.9M, cash $444.8M; SerpinPC and LB101 on track

Centessa Pharmaceuticals plc

2022-Q3 EPS reported -$1.86

Net loss $53.9M in Q3 2022 vs $40.2M in Q3 2021; R&D spend $36.7M vs $25.9M.
Cash $444.8M provides runway into 2026; no additional draw on Oberland facility.
SerpinPC pivotal program: PRESent-5 observational study starting Q4 2022; Phase 2a OLE data at ASH Dec 10.
LB101 IND submission for PD-L1xCD47 bispecific on track for late 2022.
SerpinPC granted FDA Orphan Drug Designation in September 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Centessa Pharmaceuticals plc reported the third quarter ended September 30, 2022 results: net income $53.9 million.

Period: the third quarter ended September 30, 2022
Net income: $53.9 million
Result: reported results

Exact text from the filing

Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended September 30, 2022.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Centessa Pharmaceuticals plc filing history →

Source: SEC EDGAR

accession 0001847903-22-000082

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.